1 week Ago By ABMN Staff
CIBC Private Wealth Group LLC trimmed its holdings in Biogen Inc. ( NASDAQ:BIIB – Free Report ) by 9.7% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission.
The fund owned 1,384 shares of the biotechnology company’s stock after selling 148 shares during the period. CIBC Private Wealth Group LLC’s holdings in Biogen were worth $209,000 at the end of the most recent quarter. A number of other hedge funds also recently made changes to their positions in the business.
Larson Financial Group LLC raised its stake in Biogen by 640.9% in the 4th quarter. Larson Financial Group LLC now owns 163 shares of the biotechnology company’s stock valued at $25,000 after acquiring an additional 141 shares during the period.
Lee Danner & Bass Inc. acquired a new position in shares of Biogen in the fourth quarter valued at $25,000. OFI Invest Asset Management acquired a new position in shares of Biogen in the fourth quarter valued at $32,000.
SRS Capital Advisors Inc. bought a new position in shares of Biogen in the fourth quarter valued at about $33,000. Finally, Golden State Wealth Management LLC acquired a new stake in shares of Biogen during the 4th quarter worth about $41,000.
87.93% of the stock is owned by institutional investors and hedge funds. Insider Transactions at Biogen In other news, Director Stephen A.
Sherwin sold 8,760 shares of the stock in a transaction on Friday, March 7th. The shares were sold at an average price of $150.02, for a total transaction of $1,314,175.
20. Following the completion of the sale, the director now directly owns 11,318 shares in the company, valued at $1,697,926.36.
This represents a 43.63 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through the SEC website .
0.16% of the stock is owned by corporate insiders. Biogen Trading Down 5.
9 % Biogen ( NASDAQ:BIIB – Get Free Report ) last posted its quarterly earnings data on Wednesday, February 12th. The biotechnology company reported $3.44 earnings per share for the quarter, beating analysts’ consensus estimates of $3.
43 by $0.01. Biogen had a return on equity of 14.
98% and a net margin of 16.87%. As a group, research analysts predict that Biogen Inc.
will post 15.83 earnings per share for the current year. Analyst Upgrades and Downgrades A number of brokerages recently commented on BIIB.
Royal Bank of Canada decreased their price target on shares of Biogen from $231.00 to $225.00 and set an “outperform” rating on the stock in a research note on Thursday, February 13th.
Bank Of America (Bofa) decreased their target price on Biogen from $178.00 to $163.00 and set a “neutral” rating on the stock in a research report on Tuesday, February 11th.
Argus cut Biogen from a “buy” rating to a “hold” rating in a report on Friday. Bank of America reaffirmed a “neutral” rating and issued a $178.00 price objective on shares of Biogen in a report on Tuesday, December 10th.
Finally, Citigroup dropped their target price on Biogen from $160.00 to $145.00 and set a “neutral” rating for the company in a report on Thursday, February 13th.
Eighteen investment analysts have rated the stock with a hold rating and fourteen have issued a buy rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus target price of $213.
33. View Our Latest Stock Report on Biogen About Biogen ( Free Report ) Biogen Inc discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; ADUHELM to treat Alzheimer’s disease; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE; and BYOOVIZ, a ranibizumab biosimilar referencing LUCENTIS.
Recommended Stories Want to see what other hedge funds are holding BIIB? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Biogen Inc. ( NASDAQ:BIIB – Free Report ).
Receive News & Ratings for Biogen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biogen and related companies with MarketBeat.com's FREE daily email newsletter ..
